12 SITES | 554 PATIENTS
The Early neo2 Registry is an investigator-initiated and conducted, single arm, multicenter registry that assessed the ACURATE neo2 Aortic Valve System’s performance.1
MODERATE OR SEVERE PVL*
Percent of evaluable echocardiograms demonstrating post-procedure PVL rates from the core-lab adjudicated Early neo2 Registry.2
Active PVseal: The ACURATE neo2 valve's extended sealing skirt conforms to the native valve annulus.
A separate videodensitometry angiographic core-lab adjudicated analysis compared patients implanted with the ACURATE neo2 and ACURATE neo™ valves and demonstrated significant aortic regurgitation reduction.1
Percent of evaluable echocardiograms from a separate videodensitometry angiographic core-lab analysis of the Early neo2 Registry outcomes.1,**
Clinical performance demonstrated in the Early neo2 Registry core-lab analysis showed optimized ACURATE neo2 Valve performance with a low PVL rate, best-in-class Pacemaker Implantation rate, no coronary obstruction and low overall complications.1,2